FDA Approves First Oral IL-23 Inhibitor for Moderate to Severe Plaque Psoriasis

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

A new daily pill offers a convenient alternative to injections for people with a common, itchy, and thick-skinned form of psoriasis.

First Oral IL-23 Inhibitor.Before, highly effective IL-23 blocker drugs required regular injections. This approval provides the same advanced mechanism in a convenient daily pill, eliminating needles and clinic visits for administration.
Proven in Four Phase III Trials.The drug's approval is based on strong evidence from the large ICONIC program. This robust data gives doctors and patients confidence in its effectiveness and safety profile for long-term use.
Significant Skin Clearance Achieved.In the clinical trials, Icotyde met all primary goals for clearing the thick, scaly plaques. This means patients can expect a major reduction in the visible and uncomfortable symptoms of their condition.
Expands Accessible Treatment Options.The psoriasis treatment landscape was dominated by injectables, which some patients avoid. A potent pill alternative increases choice and may lead more people to seek and stay on effective therapy.

The US Food and Drug Administration has approved Icotyde (icotrokinra), a first-of-its-kind oral medication for moderate to severe plaque psoriasis in patients aged 12 and older. The drug, developed by Johnson & Johnson and Protagonist Therapeutics, offers a new, convenient pill alternative to the injectable biologic treatments that have dominated advanced psoriasis care.

The approval is based on robust data from four Phase III trials known as the ICONIC program. Across these pivotal studies, once-daily Icotyde met all primary goals, demonstrating significant skin clearance and a favorable safety profile for both adults and adolescents. The drug is an oral targeted peptide designed to inhibit the IL-23 receptor, a well-validated pathway in psoriasis inflammation, delivering biologic-level precision in a pill format.

This mechanism represents a notable shift in patient experience. Most currently effective advanced treatments, such as AbbVie's Skyrizi and J&J's own Tremfya, are injectable biologics that target the same IL-23 pathway. Icotyde eliminates the need for regular injections, a change expected to improve comfort and long-term treatment adherence. The market impact was immediate, with AbbVie's shares falling over 5% on the news of the approval.

Looking ahead, Icotyde is also under regulatory review for plaque psoriasis in the European Union. Its potential extends beyond this condition, as it is currently being evaluated in Phase III studies for ulcerative colitis and psoriatic arthritis, and in Phase II for Crohn's disease. This broad development program underscores its potential as a pipeline-in-a-product across multiple immune-mediated diseases.

The approval marks another significant milestone for Johnson & Johnson's pharmaceutical pipeline, which includes several recent new therapy launches. With a hopeful outlook, Icotyde provides a new and convenient option for the millions living with plaque psoriasis, and its ongoing studies may soon bring this oral treatment approach to patients with other chronic inflammatory conditions.

Dermatology Icotyde IL-23 Inhibitor Plaque Psoriasis

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.